BIOA trades 340.1% below Wall Street's consensus target of $23.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BIOA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, BioAge Labs Inc. (BIOA) has a Wall Street consensus price target of $23.50, based on estimates from 6 covering analysts. With the stock currently trading at $5.34, this represents a potential upside of +340.1%. The company has a market capitalization of $201M.
Analyst price targets range from a low of $8.00 to a high of $40.00, representing a 136% spread in expectations. The median target of $23.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BIOA trades at a trailing P/E of -2.3x. Analysts expect EPS to grow -16.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KYMRKymera Therapeutics, Inc. | $10.8B | $131.73 | $141.53 | +7.4% | Buy | — | 27 |
 RVMDRevolution Medicines, Inc. | $40.9B | $192.28 | $253.47 | +31.8% | Buy | — | 25 |
 LNTHLantheus Holdings, Inc. | $6.6B | $100.61 | $102.65 | +2.0% | Buy | 18.8x | 19 |
 RYTMRhythm Pharmaceuticals, Inc. | $7.7B | $112.28 | $144.43 | +28.6% | Buy | — | 22 |
 VNDAVanda Pharmaceuticals Inc. | $230M | $3.82 | $15.50 | +305.8% | Buy | — | 19 |
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 ARDXArdelyx, Inc. | $711M | $2.88 | $13.00 | +351.4% | Buy | — | 16 |
 LLYEli Lilly and Company | $1.3T | $1354.00 | $1445.12 | +6.7% | Buy | 38.3x | 46 |
 NVONovo Nordisk A/S | $179.0B | $40.31 | $42.33 | +5.0% | Buy | 1.8x | 39 |
 ABBVAbbVie Inc. | $514.7B | $291.31 | $308.88 | +6.0% | Buy | 20.9x | 44 |
Quick answers to the most common questions about buying BIOA stock.
The consensus Wall Street price target for BIOA is $23.5, representing 340.1% upside from the current price of $5.34. With 6 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BIOA has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $23.5 implies 340.1% upside from current levels.
BIOA's current price is $5.34 with a consensus target of $23.5 (340.1% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $40 for BIOA, while the most conservative target is $8. The consensus of $23.5 represents the median expectation. These targets typically reflect 12-month expectations.
BIOA is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BIOA stock forecast based on 6 Wall Street analysts shows a consensus price target of $23.5, with estimates ranging from $8 (bear case) to $40 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BIOA, with a "Buy" consensus rating and $23.5 price target (340.1% upside). 5 of 6 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BIOA analyst price targets range from $8 to $40, a 136% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $23.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.